Novartis CEO Narasimhan Defends Company’s Decision to Withhold False Data From the FDA
Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the FDA while seeking approval for its $2.1 million gene therapy. The chief executive of Novartis on Wednesday defended...